Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema

Bibliography

• Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012;26:1045-60
   PubMed Web of Science ®Google Scholar
• Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol 2012;26:1176-93
   PubMed Web of Science ®Google Scholar
• Stuetz A, Baumann K, Grassberger M, et al. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol 2006;141:199-212
   PubMed Web of Science ®Google Scholar
• Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010;24:317-28
   PubMed Web of Science ®Google Scholar
• Ring J, Przybilla B, Ruzicka T. Handbook of atopic eczema. 2nd edition. Springer; 2006
   Google Scholar
• Aoki T, Fukuzumi T, Adachi J, et al. Re-evaluation of skin lesion distribution in atopic dermatitis. Analysis of cases 0 to 9 years of age. Acta Derm Venereol Suppl (Stockh) 1992;176:19-23
   PubMedGoogle Scholar
• Kjellman B, Hattevig G. Allergy in early and late onset of atopic dermatitis. Acta Paediatr 1994;83:229-31
   PubMed Web of Science ®Google Scholar
• Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112:S118-27
   PubMed Web of Science ®Google Scholar
• Bjorksten B. The environment and sensitisation to allergens in early childhood. Pediatr Allergy Immunol 1997;8:32-9
   PubMed Web of Science ®Google Scholar
• Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood. J Allergy Clin Immunol 1999;103:125-38
   PubMed Web of Science ®Google Scholar
• Wahn U, Wichmann H-E. Special report on allergies. Health monitoring of the federation. Metzler-Poeschel; Stuttgart: 2000
   Google Scholar
• Queille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermat 2000;42:349-50
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003;111:1153-68
   PubMed Web of Science ®Google Scholar
• Avgerinou G, Papafragkaki DK, Nasiopoulou A, et al. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 2012;26:762-7
   PubMed Web of Science ®Google Scholar
• Hui-Lan Y, Xiao-Yan H, Jian-Yong F, Zong-Rong L. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo. Pediatr Dermatol 2009;26:354-6
   PubMed Web of Science ®Google Scholar
• Ucak H, Kandi B, Cicek D, et al. The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata. J Dermatolog Treat 2012;23(6):410-20
   PubMed Web of Science ®Google Scholar
• Schwarz T, Kreiselmaier I, Bieber T, et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol 2008;59:34-40
   PubMed Web of Science ®Google Scholar
• Kim MB, Kim GW, Park HJ, et al. Pimecrolimus 1% cream for the treatment of rosacea. J Dermatol 2011;38:1135-9
   PubMed Web of Science ®Google Scholar
• Leung DY, Hanifin JM, Charlesworth EN, et al. Disease management of atopic dermatitis: a practice parameter. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Work Group on Atopic Dermatitis. Ann Allergy Asthma Immunol 1997;79:197-211
   PubMed Web of Science ®Google Scholar
• Leung DY. Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 1997;1:25-30
   Google Scholar
• Emerson RM, Williams HC, Allen BR. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J Dermatol 1998;139:73-6
   PubMed Web of Science ®Google Scholar
• Atakan N, Erdem C. The efficacy, tolerability and safety of a new oral formulation of sandimmun–sandimmun neoral in severe refractory atopic dermatitis. J Eur Acad Dermatol Venereol 1998;11:240-6
   PubMed Web of Science ®Google Scholar
• Ring J. Guidelines for treatment of atopic eczema (atopic dermatitis). JEADV 2012; In press
   Google Scholar
• Ellis C, Luger T. International consensus conference on atopic dermatitis II (ICCAD II): chairman's introduction and overview. Br J Dermatol 2003;148(Suppl 63):1-2
   PubMedGoogle Scholar
• Ellis C, Luger T, Abeck D, et al. International consensus conference on atopic dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003;148(Suppl 63):3-10
   PubMed Web of Science ®Google Scholar
• Arai T, Kouama Y, Suenaga T, Honda H. Ascomycin, an antifungal antibiotic. J Antibiot (Tokyo) 1962;15:231-2
   PubMed Web of Science ®Google Scholar
• Meingassner JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997;137:568-76
   PubMed Web of Science ®Google Scholar
• Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141:264-73
   PubMed Web of Science ®Google Scholar
• Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996;80:S40-5
   PubMedGoogle Scholar
• Bieber T. Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. J Allergy Clin Immunol 1998;102:555-7
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Chan S. Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies. J Am Acad Dermatol 1999;41:72-7
   PubMed Web of Science ®Google Scholar
• Bornhovd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001;45:736-43
   PubMed Web of Science ®Google Scholar
• De Rie MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991;71:452-4
   PubMed Web of Science ®Google Scholar
• Hermann RC, Taylor RS, Ellis CN, et al. Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacol 1988;1:246-9
   PubMedGoogle Scholar
• Reitamo S, Kayhko K, Lauerma AI, Mustakallio KK. Topical cyclosporine and contact dermatitis in guinea pig and man. Arch Dermatol 1989;125:568
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337:816-21
   PubMed Web of Science ®Google Scholar
• Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002;62:817-40
   PubMed Web of Science ®Google Scholar
• Bornhovd EC, Burgdorf WH, Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr Opin Investig Drugs 2002;3:708-12
   PubMedGoogle Scholar
• Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003;17:2205-32
   PubMed Web of Science ®Google Scholar
• Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005;5:472-84
   PubMed Web of Science ®Google Scholar
• Kalthoff FS, Chung J, Musser P, Stuetz A. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003;133:350-9
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Chong SU, Grunow K, et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001;108:275-80
   PubMed Web of Science ®Google Scholar
• Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus – an anti-inflammatory drug targeting the skin. Exp Dermatol 2004;13:721-30
   PubMed Web of Science ®Google Scholar
• Al-Daraji WI, Grant KR, Ryan K, et al. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol 2002;118:779-88
   PubMed Web of Science ®Google Scholar
• Buchau AS, Schauber J, Hultsch T, et al. Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. J Invest Dermatol 2008;128:2646-54
   PubMed Web of Science ®Google Scholar
• Santini MP, Talora C, Seki T, et al. Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci USA 2001;98:9575-80
   PubMed Web of Science ®Google Scholar
• Ortiz De Frutos FJ. New horizons in the treatment of atopic dermatitis. Allergol Immunopathol (Madr) 2002;30:134-40
   PubMedGoogle Scholar
• Novak N, Kwiek B, Bieber T. The mode of topical immunomodulators in the immunological network of atopic dermatitis. Clin Exp Dermatol 2005;30:160-4
   PubMed Web of Science ®Google Scholar
• Kapp A, Allen BR, Reitamo S. Atopic dermatitis management with tacrolimus ointment (Protopic). J Dermatol Treat 2003;14:5-16
   PubMedGoogle Scholar
• Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 2005;65:827-58
   PubMed Web of Science ®Google Scholar
• Graham-Brown RA, Grassberger M. Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract 2003;57:319-27
   PubMed Web of Science ®Google Scholar
• Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004;5:643-55
   PubMed Web of Science ®Google Scholar
• Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004;269:29-35
   PubMed Web of Science ®Google Scholar
• Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003;88:969-73
   PubMed Web of Science ®Google Scholar
• Van Leent EJ, Ebelin ME, Burtin P, et al. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981 in patients with atopic dermatitis. Dermatology 2002;204:63-8
   PubMed Web of Science ®Google Scholar
• Ling M, Gottlieb A, Pariser D, et al. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. J Dermatolog Treat 2005;16:142-8
   PubMed Web of Science ®Google Scholar
• Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis–a multicenter, 3-week, open-label study. Pediatr Dermatol 2005;22:465-71
   PubMed Web of Science ®Google Scholar
• Rappersberger K, Komar M, Ebelin ME, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002;119:876-87
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Griffiths CE, Ho VC, et al. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol 2005;152:1219-27
   PubMed Web of Science ®Google Scholar
• Zollinger M, Waldmeier F, Hartmann S, et al. Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos 2006;34:765-74
   PubMed Web of Science ®Google Scholar
• Van Leent EJ, Graber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998;134:805-9
   PubMed Web of Science ®Google Scholar
• Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001;144:781-7
   PubMed Web of Science ®Google Scholar
• Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788-94
   PubMed Web of Science ®Google Scholar
• Hebert AA, Warken KA, Cherill R. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases. Semin Cutan Med Surg 2001;20:260-7
   PubMed Web of Science ®Google Scholar
• Van Leent EJ, De Vries HJ, Ebelin ME, et al. Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year. J Dermatolog Treat 2007;18:19-22
   PubMed Web of Science ®Google Scholar
• Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2
   PubMed Web of Science ®Google Scholar
• Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-84
   PubMed Web of Science ®Google Scholar
• Jensen JM, Scherer A, Wanke C, et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy 2012;67:413-23
   PubMed Web of Science ®Google Scholar
• Jensen JM, Ahrens K, Meingassner J, et al. Differential suppression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids. Exp Dermatol 2011;20:783-8
   PubMed Web of Science ®Google Scholar
• Weissenbacher S, Traidl-Hoffmann C, Eyerich K, et al. Modulation of atopy patch test and skin prick test by pretreatment with 1% pimecrolimus cream. Int Arch Allergy Immunol 2006;140:239-44
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Frank R, Kroth J, Ruzicka T. Proactive therapy of atopic eczema–an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges 2009;7:117-21
   PubMed Web of Science ®Google Scholar
• Rappersberger K, Meingassner JG, Fialla R, et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996;106:701-10
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Graeber M, Brautigam M, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139:992-6
   PubMed Web of Science ®Google Scholar
• Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs 2000;9:69-77
   PubMed Web of Science ®Google Scholar
• Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology 2007;215:45-54
   PubMed Web of Science ®Google Scholar
• Kim GK, Rosso JD. Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis. J Clin Aesthet Dermatol 2013;6:29-35
   PubMedGoogle Scholar
• Gollnick H, Luger T, Freytag S, Brautigam M. StabiEL: stabilization of skin condition with Elidel–a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid. J Eur Acad Dermatol Venereol 2008;22:1319-25
   PubMed Web of Science ®Google Scholar
• Stander S, Stander H, Seeliger S, et al. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol 2007;156:1020-6
   PubMed Web of Science ®Google Scholar
• Langley RG, Luger TA, Cork MJ, et al. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology 2007;215:27-44
   PubMed Web of Science ®Google Scholar
• Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003;142:155-62
   PubMed Web of Science ®Google Scholar
• Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006;117:e118-28
   PubMed Web of Science ®Google Scholar
• Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005;52:247-53
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001;144:507-13
   PubMed Web of Science ®Google Scholar
• Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007;157:954-9
   PubMed Web of Science ®Google Scholar
• Lerche C, Wulf HC. Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs. Dermatol Rep 2010;2:e13
   Google Scholar
• Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007;214:289-95
   PubMed Web of Science ®Google Scholar
• Ring J, Barker J, Behrendt H, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005;19:663-71
   PubMed Web of Science ®Google Scholar
• Shiga T, Yokogawa M, Nakajima K, et al. Topical tacrolimus treatment does not facilitate photocarcinogenesis in cancer-prone mice. J Dermatol Sci 2012;68:112-15
   PubMed Web of Science ®Google Scholar
• Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol 2006;15:342-6
   PubMed Web of Science ®Google Scholar
• Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007;127:808-16
   PubMed Web of Science ®Google Scholar
• Hultsch T. Elidel (pimecrolimus) cream 1% safety update February 2005. Internet. 2005. Available from: http://www.fda.gov/ohrms/dockets/ac/05/slides/2005–4089s2_02_02_Novartis%20Core%20Safety%20(CS).pdf
   Google Scholar
• Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005;211:174-87
   PubMed Web of Science ®Google Scholar
• Ring J, Mohrenschlager M, Henkel V. The US FDA ‘black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008;31:185-98
   PubMed Web of Science ®Google Scholar
• Orlow SJ. Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues. Paediatr Drugs 2007;9:289-99
   PubMedGoogle Scholar
• Food and Drug Administration Pediatric Advisory Committee F. 2006
   Google Scholar
• Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 2011;165:465-73
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol 2013;14:163-78
   PubMed Web of Science ®Google Scholar